Stay updated on Galinpepimut-S vs. Best Available Therapy in AML Maintenance Clinical Trial

Sign up to get notified when there's something new on the Galinpepimut-S vs. Best Available Therapy in AML Maintenance Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Galinpepimut-S vs. Best Available Therapy in AML Maintenance Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The site footer’s revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-10-30T11:19:10.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces updates about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    0.7%
    Check dated 2026-10-23T11:41:17.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-16T13:47:51.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-09T13:22:54.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 has been added to the study's record history. The prior revision v3.6.6 has been removed from the visible changes.
    Difference
    0.1%
    Check dated 2026-09-18T20:10:15.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The history now shows a new revision labeled Revision: v3.6.6, superseding Revision: v3.6.5, representing an update to the page's versioning record.
    Difference
    0.1%
    Check dated 2026-08-28T07:47:25.000Z thumbnail image

Stay in the know with updates to Galinpepimut-S vs. Best Available Therapy in AML Maintenance Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Galinpepimut-S vs. Best Available Therapy in AML Maintenance Clinical Trial page.